The New GI-MAP Microbial Markers - What Clinicians Need to Know
Please Note
GI-MAP has been further enhanced since this post was published in 2018. Additional test information is available at:
The GI-MAP™ comprehensive stool analysis now includes four new commensal and opportunistic biomarkers (A. muciniphila, F. prausnitzii, Methanobacteriaceae (family), and Fusobacterium spp.). The carefully curated new biomarkers provide enhanced clinical insights based on the latest medical research. Further, the additional markers were added based on their ability to be modified using known clinical approaches.
In this presentation, Dr. Tom Fabian, will take clinicians on a marker-by-marker journey that explains the significance the new markers have on patient health, how to interpret them, and how to work with them in clinical practice.
Author Tom Fabian, Ph.D., CNTP
Dr. Fabian is a leading expert on the role of the microbiome in health, immune function, chronic disease, and aging. As a translational scientist, his primary focus is on the clinical application of microbiome research in the integrative and functional medicine space. He received his PhD in molecular biology from the University of Colorado, Boulder, and has worked as a biomedical researcher in the biotechnology industry...
The opinions expressed in this presentation are the author's own. Information is provided for informational purposes only and is not meant to be a substitute for personal advice provided by a doctor or other qualified health care professional. Patients should not use the information contained herein for diagnosing a health or fitness problem or disease. Patients should always consult with a doctor or other health care professional for medical advice or information about diagnosis and treatment.